Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bispecific Antibodies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06822972
What this trial is testing

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Duke University 27
Early research (Phase 1)Study completedNCT03309111
What this trial is testing

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA 81
Large-scale testing (Phase 3)Looking for participantsNCT06712355
What this trial is testing

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Who this might be right for
Extensive-stage Small-cell Lung Cancer
BioNTech SE 621
Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Large-scale testing (Phase 3)Study completedNCT02393859
What this trial is testing

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Leukemia, Acute Lymphoblastic
Amgen 111
Testing effectiveness (Phase 2)Ended earlyNCT04999605
What this trial is testing

AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer

Who this might be right for
Ovarian NeoplasmsRecurrent Ovarian CarcinomaRelapsed Ovarian Cancer+1 more
Akeso 8
Early research (Phase 1)Active Not RecruitingNCT04648202
What this trial is testing

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Who this might be right for
Advanced CancerMetastatic Cancer
invoX Pharma Limited 82
Testing effectiveness (Phase 2)Looking for participantsNCT06280105
What this trial is testing

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Who this might be right for
Hepatocellular Carcinoma
Meng Chao Hepatobiliary Hospital of Fujian Medical University 40
Very early researchNot Yet RecruitingNCT07066436
What this trial is testing

ImmunoMRI for Assessment of Tumor-associated Macrophages

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
Medical University of Vienna 60
Early research (Phase 1)Looking for participantsNCT07101328
What this trial is testing

LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Who this might be right for
Lymphoma, Non-HodgkinB-cell LymphomaLymphoma, Large B-Cell, Diffuse+4 more
Eli Lilly and Company 215
Testing effectiveness (Phase 2)Active Not RecruitingNCT04623541
What this trial is testing

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Who this might be right for
Relapsed/Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's Syndrome+1 more
Genmab 194
Testing effectiveness (Phase 2)Study completedNCT06266091
What this trial is testing

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Who this might be right for
Malignant Ascites
Wuhan YZY Biopharma Co., Ltd. 115
Not applicableApproved For MarketingNCT05733650
What this trial is testing

Expanded Access Program for Epcoritamab

Who this might be right for
Large B-cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+2 more
Genmab
Large-scale testing (Phase 3)Looking for participantsNCT07221253
What this trial is testing

Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Who this might be right for
Biliary Tract Cancer
AstraZeneca 1,100
Early research (Phase 1)Looking for participantsNCT04686305
What this trial is testing

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 304
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Early research (Phase 1)UnknownNCT05442996
What this trial is testing

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor, Adult
Shanghai Henlius Biotech 30
Testing effectiveness (Phase 2)WithdrawnNCT03524261
What this trial is testing

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Fuda Cancer Hospital, Guangzhou
Testing effectiveness (Phase 2)Study completedNCT03929666
What this trial is testing

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Who this might be right for
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals 74
Early research (Phase 1)Looking for participantsNCT07612176
What this trial is testing

NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc. 155
Next Page